Chromogranin A: Is It a Useful Marker of Neuroendocrine Tumors?
- 20 May 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (15), 1967-1973
- https://doi.org/10.1200/jco.2006.10.1535
Abstract
We evaluated the pattern of chromogranin A (CgA) plasma levels in a large number of patients with neuroendocrine tumors (NETs), in a series of patients with chronic atrophic gastritis (CAG) with and without enterochromaffin-like (ECL) cell hyperplasia, and in healthy participants (HPs). Two hundred thirty-eight patients with NETs, 42 patients with CAG with or without ECL cell hyperplasia, and 48 HPs were studied. All patients underwent a baseline visit, biochemical routine check-up, imaging techniques, endoscopy, and histologic determination. CgA plasma levels were higher in patients with NETs compared with CAG patients or HPs (P < .001). In the NET group, we observed higher CgA levels in patients with diffuse disease compared with patients with local or hepatic disease (P < .001). CgA plasma levels were significantly higher in patients with Zollinger-Ellison syndrome compared with other types of endocrine tumors (P < .001). We found the best cutoff range between HPs and NET patients to be 18 to 19 U/L (sensitivity, 85.3%; specificity, 95.8%). Comparing all participants without neoplasia (HPs, CAG patients, and disease-free patients) and patients with endocrine tumors, the best cutoff range was 31 to 32 U/L (sensitivity, 75.3%; specificity, 84.2%). Setting the specificity at 95%, the cutoff range was 84 to 87 U/L (sensitivity, 55%). Our study confirms the high specificity and sensitivity of CgA in diagnosing an endocrine tumor. It is necessary to use a cutoff range of 84 to 87 U/L to obtain a high specificity in diagnosing NETs, with the aim of excluding patients in whom the CgA was elevated as a result of other non-neoplastic diseases.Keywords
This publication has 24 references indexed in Scilit:
- Endocrine Tumors of the Ileum: Factors Correlated with SurvivalNeuroendocrinology, 2006
- Endocrine pancreatic tumors: factors correlated with survivalAnnals Of Oncology, 2005
- Interest of Chromogranin A for diagnosis and follow‐up of endocrine tumoursClinical Endocrinology, 2004
- Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomasCancer, 2003
- Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the -Subunit of Glycoprotein HormonesJournal of Clinical Endocrinology & Metabolism, 1997
- Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumoursJournal of Endocrinology, 1995
- Chromogranin a and Pancreastatin-Like Immunoreactivity in Serum of Gastrinoma PatientsActa Oncologica, 1993
- Serum chromogranin A in the diagnosis and follow‐up of neuroendocrine tumors of the gastroenteropancreatic tractWorld Journal of Surgery, 1992
- Peptide Hormones as Tumor Markers in Neuroendocrine Gastrointestinal TumorsActa Oncologica, 1991
- Secretion of Chromogranin A by Peptide-Producing Endocrine NeoplasmsNew England Journal of Medicine, 1986